Synlogic

Synlogic is a clinical-stage biotech company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases.

[Synlogic @synlogic_tx]

Last week, we announced the end of our PKU study, Synpheny-3, and that Synlogic will cease operations. Our sincere thanks to all who worked with us, and especially to the PKU & HCU communities, who inspired us and enabled our pursuit of new medicines. https://t.co/kf5noLyOqJ

[Synlogic @synlogic_tx]

The #PKU Synpheny-3 Clinical Trial is now available in Nashville, TN! Virtual, hybrid, and in-person options for participation are available.

Scan the QR code or visit https://t.co/9naeZ2VlI4 to learn more.

[Synlogic @synlogic_tx]

The #PKU Synpheny-3 Clinical Trial is now available in Chicago, IL! Virtual, hybrid, and in-person options for participation are available.

Scan the QR code to learn more!

[Synlogic @synlogic_tx]

Congrats authors! Proud of this manuscript on the journey of SYNB1353, our drug candidate for classical #HCU, published in Cell Host & Microbe: :https://t.co/jg1AVTMPRX @CellPressNews #inbornerrors #homocystinuria #rarediseases #synbio #syntheticbiology

[Synlogic @synlogic_tx]

Last year, SYNB1934 received the FDA's Rare Pediatric Disease, Fast Track, and Orphan Drug designations, Orphan designation from the EMA, AND the WHO's go-ahead for the non-proprietary name: labafenogene marselecobac! Learn more: https://t.co/tqw5MEmKQn

[Synlogic @synlogic_tx]

Learn about Synlogic's focus on rare metabolic diseases, and our lead asset, SYNB934, now in Phase 3 with a milestone-rich year ahead, in this recent webcast: https://t.co/WsWPrze0dK Thank you @SidotiResearch! #sidoti $SYBX #SYBX #biotechstocks $XBI

[Synlogic @synlogic_tx]

A reminder to those affected by #PKU! #phenylketonuria

[Synlogic @synlogic_tx]

3 major milestones in the next 18 months for our #Phase3 study in PKU. Learn more here: https://t.co/rOadDkkOF9 $SYBX #SYBX #biotechstocks #investmentideas #catalysts #raredisase

[Synlogic @synlogic_tx]

The #PKU Synpheny-3 Clinical Trial is now available in Gainesville, FL! Virtual, hybrid, and in-person options for participation are available.

Scan the QR code to learn more and to speak to Synlogic's clinical trial case manager.

[Synlogic @synlogic_tx]

Among 2023's wins: our IP team's securing protection for the innovations behind SYNB1934 (a.k.a. labafenogene marselecobac). Read up on our accomplishments and upcoming milestones: https://t.co/tqw5MEmKQn #biotechinnovation $SYBX #SYBX #biotechstocks #investmentideas

[Synlogic @synlogic_tx]

The #PKU Synpheny-3 Clinical Trial is now available in Charleston, SC! Virtual, hybrid, and in-person options for participation are also available.

Scan the QR code to learn more and to speak to Synlogic's clinical trial case manager.

[Synlogic @synlogic_tx]

Ramp up on SYBX and our upcoming milestones! Last week's webcast can be seen here: https://t.co/WsWPrze0dK Thank you @SidotiResearch! #sidoti $SYBX #SYBX #biotechstocks #investmentideas #growthstocks #valuestocks

[Synlogic @synlogic_tx]

Curious about PKU, and why Phe lowering is so important in this rare metabolic disease? In this brief clip (2 mins), Dr. Hope Northrup, medical geneticist and expert in #inbornerrors, explains: https://t.co/MhC4w54un7 #SYBX $SYBX #rarediseases #drugdevelopment

[Synlogic @synlogic_tx]

Learn about our ongoing, pivotal study in #PKU in this brief (~2 min) video: https://t.co/stm7ZUOhYW or visit https://t.co/b6ltF0RvTD #phenylketonuria #rarediseases #biotechstocks $SYBX

[Synlogic @synlogic_tx]

The #PKU Synpheny-3 Clinical Trial is now available in Aurora, CO! Virtual, hybrid, and in-person options for participation are available.

Scan the QR code to learn more and to speak to Synlogic's clinical trial case manager. #CUAnschutz #CUMedicine @CUAnschutz @CUMedicine

[Synlogic @synlogic_tx]

Get the latest on Synlogic's important work in rare metabolic diseases, and exciting upcoming milestones for our Ph 3 program in PKU. Watch here: https://t.co/WsWPrze0dK Thank you @SidotiResearch! #sidoti $SYBX #SYBX #biotechstocks #growthstocks #valuestocks

[Synlogic @synlogic_tx]

The #PKU Synpheny-3 Clinical Trial is now available in Palo Alto, CA! Virtual, hybrid, and in-person options for participation may be available.

To learn more and to speak to our Synlogic clinical trial case manager, visit https://t.co/9naeZ2VlI4!

[Synlogic @synlogic_tx]

Synpheny-3 clinical trial is open in the US! In this video, Synlogic team members answer FAQs we've received about the ongoing Synpheny-3 clinical trial.

Learn more: https://t.co/k4k413tQbm

[Synlogic @synlogic_tx]

SynPheny-3 Clinical Trial is actively recruiting participants living with #PKU. We've made participation flexible with a fully virtual option, so you can participate from almost anywhere in the US!

Learn more and sign up today. #PKU #ClinicalTrial #SynPheny3

[Synlogic @synlogic_tx]

ICYMI! Learn from our team about Synlogic's late-stage programs in rare metabolic diseases, and exciting upcoming milestones for our Ph 3 program in PKU: https://t.co/WsWPrze0dK Thank you @SidotiResearch! #sidoti $SYBX #SYBX #biotechstocks #growthstocks #valuestocks